Emerging treatments include SGLT2i for their reno-cardiometabolic benefits, GLP1-RA due to their reduction of HF and CKD progression, PCSK9i to reduce ASCVD risk, and sGCa for endothelial and cardiac function improvements. Here, GLP1R is linked to hydrops fetalis.